Knight Therapeutics Stock
Your prediction
Pros and Cons of Knight Therapeutics in the next few years
Pros
?
M***** P*******
?
S********** s********
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Knight Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Knight Therapeutics | 1.670% | -1.639% | 3.448% | 57.068% | 61.290% | 84.049% | 77.515% |
| Biomark Diagnostics Inc. | 1.270% | -0.625% | 0.000% | 61.421% | 15.217% | 110.596% | 142.748% |
| MicroPlanet Technology Corp | 0.000% | 0.000% | 0.800% | -1.563% | -17.105% | -28.409% | -17.647% |
| Avricore Health Inc. | 7.840% | -10.526% | -19.048% | -42.045% | 10.870% | -74.752% | -78.017% |
News
Knight-Swift Transportation Q2 Earnings Call Highlights
Key Points
- Interested in Knight-Swift Transportation Holdings Inc.? Here are five stocks we like better.
- Knight-Swift said the truckload market tightened sharply in Q2 2026, with spot rates
Why Shares in Knight-Swift Transportation Crashed This Week
Knight-Swift Transportation (NYSE: KNX) is the largest full truckload carrier in the U.S., and it's always going to be at the center of the never-ending debate over where trucking companies are in
Integra LifeSciences Says Transformation Is Working as SurgiMend Relaunch Nears
Integra LifeSciences (NASDAQ:IART) is keeping its core strategy intact following a leadership change that returned Stuart to the roles of chairman and chief